Global pharmaceutical giant AstraZeneca has welcomed the new guidance from Australia’s Vaccine Advisory Group that younger Sydney residents should seriously consider taking their coronavirus vaccine, stating that their product is a key weapon in the fight against Delta variant.
The Australian Technical Advisory Group (ATAGI) issued a statement on Saturday warning that all adults in the Greater Sydney area should “seriously consider getting vaccinated with any available vaccine,” including that from AstraZeneca. This was due to the increased risk of COVID-19 and supply limitations of the Pfizer vaccine.
In a rare foray into the debate over Australia’s vaccine policy, the British-Swedish pharmaceutical giant said it supported the new medical advice.
“Regulatory authorities around the world have stated that the benefit of using our vaccine significantly outweighs the risks in all adult age groups, and this has been reiterated by ATAGI and the Therapeutic Goods Administration (TGA), particularly in the context Delta outbreaks, ”said an AstraZeneca Australia spokeswoman this morning.
AstraZeneca, which has contracts with the federal government and CSL for CSL to manufacture 50 million doses of the vaccine on land, has been forced to advocate for the safety of its product in recent months after ATAGI issued guidance warning not to it was the preferred vaccine for younger Australians. due to very rare blood clot risks.
However, Australia’s Vaccine Advisory Group highlighted on Saturday that “in a large outbreak, the benefits of the COVID-19 AstraZeneca vaccine outweigh the risk of rare side effects for all age groups.”
New South Wales recorded 141 cases of the virus on Sunday.
“In the context of the current COVID-19 risk in NSW and with ongoing limitations in the supply of vaccines from Comirnaty (Pfizer), all adults in the greater Sydney area should seriously consider the benefits of a protection early with the COVID-19 AstraZeneca vaccine rather than waiting for alternative vaccines, ”ATAGI said.
AstraZeneca has always maintained that it respects the views of ATAGI and the Therapeutic Goods Administration, but has been keen to highlight that the age guide applied to its vaccine in Australia was made in an environment of low or no community transmission of the virus.